Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18356265 | 0.98 | MEN1 (0.53) | MEN1KMT2ALMNAMAPTHTT | |
| SCHEMBL26265666 | 0.91 | LMNA (0.49) | MEN1KMT2ALMNAMAPTHTT | |
| SCHEMBL18355961 | 0.89 | LMNA (0.51) | MEN1KMT2ALMNAMAPTHTT | |
| SCHEMBL16260534 | 0.86 | LMNA (0.48) | MEN1KMT2ALMNAMAPTHTT | |
| SCHEMBL17080656 | 0.85 | LMNA (0.52) | MEN1KMT2ALMNAMAPTHTT | |
| SCHEMBL26265704 | 0.85 | LMNA (0.44) | MEN1KMT2ALMNAMAPTHTT | |
| SCHEMBL18355571 | 0.82 | LMNA (0.49) | MEN1KMT2ALMNAMAPTHTT | |
| SCHEMBL18355975 | 0.80 | MEN1 (0.42) | MEN1KMT2ALMNAMAPTHTT | |
| SCHEMBL30616857 | 0.80 | LMNA (0.45) | MEN1KMT2ALMNAMAPTHTT | |
| SCHEMBL15999479 | 0.79 | ALDH1A1 (0.53) | MEN1KMT2ALMNAMAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230355800-A1 | METHODS AND COMPOSITIONS FOR SYNTHESIS OF THERAPEUTIC NANOPARTICLES | Dantari, Inc. | 2023-11-09 | — | — | US | disclosed |
| US-11738092-B2 | Methods and compositions for synthesis of therapeutic nanoparticles | Dantari, Inc. (US) | 2023-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11738092-B2 | Methods and compositions for synthesis of therapeutic nanoparticles | CD47, CD44, HCCS | MEN1 2996/4885KMT2A 3470/4885LMNA 1294/4885 |
| US-20230355800-A1 | METHODS AND COMPOSITIONS FOR SYNTHESIS OF THERAPEUTIC NANOPARTICLES | CD47, CD44, HCCS | MEN1 2996/4885KMT2A 3470/4885LMNA 1294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.